A combination of the Bristol-Myers Squibb Co. checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) diminished the size of previously untreated renal cell carcinomas (RCC) for more people than Pfizer Inc.'s Sutent (sunitinib) during a closely watched phase III trial.